Stock Quality:
Last 30 days
-6.4%
Last 90 days
-21.6%
Trailing 12 Months
-94.2%
RLMD RSI Chart
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
Revenue Breakdown
|
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 0 | 0 | 0 | 6.2M |
2020 | 0 | 0 | 818.3K | 0 |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 0 |
2017 | 0 | 96.4K | 0 | 0 |
2014 | 66.0K | 0 | 0 | 0 |
2013 | 6.5K | 5.8K | 5.1K | 35.6K |
2012 | 0 | 0 | 7.9K | 7.2K |
CEO | Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD |
---|---|
WEBSITE | relmada.com |
SECTOR | Healthcare |
INDUSTRY | Biotechnology |
EMPLOYEES | 14 |